Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q39214063

about

The Response of Macrophages and Neutrophils to Hypoxia in the Context of Cancer and Other Inflammatory Diseases Hypoxia-inducible factors as molecular targets for liver diseases Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy.Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.The role of hypoxia inducible factor-1 in hepatocellular carcinoma.Association of Notch1 with vasculogenic mimicry in human hepatocellular carcinoma cell lines The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway.Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.Time-dependent effect of hypoxia on tumor progression and liver progenitor cell markers in primary liver tumors.Induction of cellular prion protein (PrPc) under hypoxia inhibits apoptosis caused by TRAIL treatment.Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma.Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.A preliminary study of ALPPS procedure in a rat model.Effects of curcumin in pediatric epithelial liver tumors: inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB- and the beta-catenin pathways.HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells.Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma.Tylophorine Analog DCB-3503 Inhibited Cyclin D1 Translation through Allosteric Regulation of Heat Shock Cognate Protein 70 Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer.LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review).Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review.Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility.Hypoxia inducible factors in hepatocellular carcinoma

P2860

Q26749138-2F9CF23A-5542-4735-B2BF-0C1FA850B936 Q26752304-E8E02943-600A-4D7F-8923-F6A1A16CADB5 Q26781520-5C7D2144-1D93-4E0B-BBE6-3D73CA0B81D0 Q26824909-47CDADE1-E2E6-4D8B-9A56-228439B86627 Q28383116-D6C46D3B-B574-4B98-89A5-FD5CE221FC7A Q28384683-E1BA63F6-1B6D-4A20-98FB-CDE0DF88DA8B Q28539940-B1564A90-AE68-48F8-B22B-E83DEEA7DC88 Q28542821-4F0ECC4C-A11B-43A5-A017-DD08B13D6B4F Q33555302-2F2875EB-F12A-4384-B79C-A9819D91C5AF Q33591514-3BA2ADEC-9FFD-44A7-BBB7-DEC83750C600 Q33713544-B3719236-876B-4CA4-9EA7-F17DB3BD27C7 Q33914603-4AD10C04-BC03-473C-ABF9-B6FD33B540C2 Q34371351-BA5D3211-D7BE-486D-B373-AD4F87FDE8AF Q34483637-B65E6820-4F1A-460D-A2F8-F5BFC18D9213 Q34728237-DF770DA9-7AE5-4B04-AC94-07B0E2515B66 Q35078001-9FF76549-D8CB-45E0-8B79-793AAA1ECF5E Q35582077-571D8537-DCA4-4DE6-9B9A-0BC0658F27E6 Q35741681-517298EE-DB99-473C-9BA1-26E8F6A0EFDC Q35843846-ED619860-7111-4CCE-AC90-D3AFE2E1F382 Q35870450-5A149465-5413-4045-83CF-509E2369DBB7 Q36212847-3FFFC804-79B6-4B8B-9A01-63AA2D345987 Q36232448-70C5D828-2578-461A-ABC2-25FA3C77256C Q36343340-98F76531-EA7F-4D62-AAD0-9145B08ED44A Q36562132-2DB228C6-AD6A-4A49-98F3-DC2BEA3F10F0 Q36729450-309C0B7D-A19C-4671-85BF-2946E785CB4C Q36916380-2DAD7617-5FC6-481E-B7BD-F2BB703FB8E6 Q37049104-F12989E1-9C53-43EB-953B-3D4484279EA1 Q37109676-00BE0D84-9131-497C-8BD0-BA131BCA6033 Q37141152-C59FB0DE-0301-4DF7-8EBF-BB15491B289D Q37215717-5CEE51C7-EB48-461B-B329-AC1F34FAD9BE Q37233007-059340BE-FAC4-45F3-B256-CE765CCDC8AD Q37244398-11B8DAF4-61DA-4F71-907E-6C44A7189108 Q37306916-3D23D745-B5DC-4614-93D9-07BF85DCCC36 Q37369888-BED70356-8C32-4D5F-A1EA-BF763E3E7238 Q37493227-AE38E38F-AF4A-4224-BE56-DFFA57FAE4AE Q37699304-E85DFFA8-A65D-453E-BB20-D517FC11A5A8 Q38185910-A178DA57-A2A7-4466-B412-7B63D7AF7788 Q38264330-C54EA955-3A6E-463B-A33C-E148157878F0 Q38450711-06AF752F-4265-4E2C-98EF-2FC99CB8D26D Q38685135-6E62E93E-31C6-4A3F-B2BF-3FCE33A384A4

P2860

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q39214063

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Hypoxia-mediated sorafenib res ...... n in hepatocellular carcinoma.

@en

Hypoxia-mediated sorafenib res ...... n in hepatocellular carcinoma.

@nl

type

label

Hypoxia-mediated sorafenib res ...... n in hepatocellular carcinoma.

@en

Hypoxia-mediated sorafenib res ...... n in hepatocellular carcinoma.

@nl

prefLabel

Hypoxia-mediated sorafenib res ...... n in hepatocellular carcinoma.

@en

Hypoxia-mediated sorafenib res ...... n in hepatocellular carcinoma.

@nl

P1433

Q39214063-D9BE055D-0DCF-4E62-BD16-61C9438FD165

P1476

Q39214063-8A884DD1-D583-4EE1-BD54-8EE3243A61C4

P2093

Q39214063-0CB9931A-50BC-4EE6-BD60-52DF77D081D3

Q39214063-3F9AFFF8-55F8-4A4E-8F65-94199EC945F4

Q39214063-49402A88-3864-4FD8-838B-7A2B487EB12D

Q39214063-5A010A1C-F7D6-4F90-B063-CAD0B3031760

Q39214063-95D7CC08-C470-4FF9-AF13-0DC305A8A99D

Q39214063-960F8F6A-C9C3-4ECC-91CB-9DF8E144F191

Q39214063-9EAD811F-71A3-4004-AC9C-ED569CC6921E

Q39214063-A1E4226E-28E7-402F-A7CB-947A29267F97

Q39214063-AA0CF689-212B-4BDC-B91A-9C41262B1E1D

Q39214063-F30B30CD-F716-43C2-9DD9-AEFFB14F1661

P2860

Q39214063-080D7F03-2FDE-43C1-B8F7-341712DFB62A

Q39214063-259F9381-DDCB-40E7-93E3-A97C69F30715

Q39214063-3284840E-E3D7-4343-B746-AF483467C8D6

Q39214063-4002C17B-ABAC-496B-A9BE-9627E5FDFF3A

Q39214063-4538E601-3444-4F45-8E48-39250C9806D2

Q39214063-544AB3FA-1EDB-46EB-A89F-81A244E4AEDD

Q39214063-618FCF3A-388D-485C-8868-9B138D6C1465

Q39214063-771E0A3A-7ACD-4EB9-8D86-96821C9D89C2

Q39214063-7811CBC7-344D-4203-8468-CCCEAC76FC2D

Q39214063-7972ED27-8D40-4040-A65E-A1344CC1D765

P304

Q39214063-8211B8F3-06A4-4F6A-BDFC-B4FDFDD4D1D8

P31

Q39214063-D3E8D866-6761-4C96-90CE-7367284829CA

P356

Q39214063-1E355F3C-29B6-481B-8EB4-D06DFC074ADA

P407

Q39214063-5B985419-CEFF-4958-BE61-C08CD2E43FEC

P433

Q39214063-E2C62057-F547-47E0-8C39-11D71D3C0429

P478

Q39214063-D999A71B-1BFF-42A6-9F49-34B1D7CE3D49

P50

Q39214063-7AA2E54E-19F2-4CE0-A76F-5180C1F84B0D

P577

Q39214063-195A251F-01E3-4678-855D-1CA338E8338E

P698

Q39214063-477DD03D-A38E-462D-8805-5F791F85C1ED

P921

Q39214063-C99C8A2A-5259-4A1C-8447-F345CF602E5A

P356

P1433

P1476

Hypoxia-mediated sorafenib res ...... on in hepatocellular carcinoma

@en

P2093

Dalong Yin

http://www.w3.org/2001/XMLSchema#string

Haitao Liu

http://www.w3.org/2001/XMLSchema#string

Jiabei Wang

http://www.w3.org/2001/XMLSchema#string

Jiaren Liu

http://www.w3.org/2001/XMLSchema#string

Lantian Tian

http://www.w3.org/2001/XMLSchema#string

Lianxin Liu

http://www.w3.org/2001/XMLSchema#string

Luoluo Wang

http://www.w3.org/2001/XMLSchema#string

Ruipeng Song

http://www.w3.org/2001/XMLSchema#string

Tongsen Zheng

http://www.w3.org/2001/XMLSchema#string

Xiang Fang

http://www.w3.org/2001/XMLSchema#string

P2860

The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity

Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Sorafenib in advanced hepatocellular carcinoma

Drug resistance and the solid tumor microenvironment

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinoma

Targeted therapies for hepatocellular carcinoma.

EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.

Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

P304

1847-1857

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26224

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23299930

http://www.w3.org/2001/XMLSchema#string

P921